Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Rare HER2 missense mutations promote the oncogenic signaling and migration of breast cancer

ABSTRACT: Proteomic and phosphoproteomic data for rare HER2 missense mutations

ORGANISM(S): Homo Sapiens

SUBMITTER: Yun Chen

PROVIDER: PXD040988 | iProX | Mon Mar 20 00:00:00 GMT 2023

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Similar Datasets

IDH mutations are rare events in SHH medulloblastoma

Project description:IDH mutations are rare events in SHH medulloblastoma

| PRJNA1315206 | ENA

Transcriptome splicing analysis in K562 cells expressing rare and private spliceosomal mutations

Project description:Genes encoding RNA splicing factors are frequently mutated in clonal hematopoesis and diverse cancers. Most spliceosomal mutations affect specific hotspot residues, causing changes in exon and splice site recognition that promote disease. However, a subset of patients carry splicesomal mutations in non-hotspot residues, and their contribution to disease are unknown. Here we systematically characterized the function of several rare and private spliceosomal mutations in order to determine their potential disease relevance. We discovered that several rare and private spliceosomal mutations phenocopy the mechanistic splicing alterations induced by their "hotspot" counterparts. Our data suggest that many rare and private spliceosomal mutations contribute to disease pathogenesis.

2019-12-02 | GSE135732 | GEO

IDH mutations are rare events in SHH medulloblastoma

Project description:Hotspot mutations in IDH1 or IDH2 have been discovered as a frequent oncogenic event in gliomas in 2009. According to the most recent version of the WHO classification of brain tumors from 2021, such mutations define what is now called astrocytoma, IDH-mutant and oligodendroglioma, IDH-mutant and 1p/19q-codeleted. Approximately 85% of these mutations are IDH1:p.R132H mutations with other amino acid exchanges at codon 132 of IDH1 and codon 172 of IDH2 being rare. Of note, no other brain tumor entity has been reported so far to carry any recur-rent IDH mutations. Here, we describe a series of 12 medulloblastomas with four novel and eight previously published cases. Eight of these cases carry IDH1:p.R132C mutations, one of them harbors an IDH1 R132L and one of them an IDH2:p.R172M mutation. Patients have a mean age of 27 years (range: 6-50) and suffer all from medulloblastoma of the SHH type.

2025-12-09 | GSE307314 | GEO

Breast cancer mutations HER2V777L and PIK3CAH1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.

Project description:In metastatic breast cancer, HER2 activating mutations frequently co-occur with mutations in the PIK3CA, TP53, or E-cadherin genes. Of these co-occurring mutations, HER2 and PIK3CA mutations are the most prevalent gene pair, with approximately 40% of HER2 mutated breast cancers also having activating mutations in PIK3CA. To study the effects of co-occurring HER2 and PIK3CA mutations, we bred genetically engineered mice with the HER2V777L; PIK3CAH1047R transgenes (HP mice) and studied the resulting breast cancers both in vivo as well as ex vivo using cancer organoids.

2023-07-21 | GSE216871 | GEO

Whole exome sequencing in Alopecia Areata identifies rare mutations in KRT82

Project description:Whole exome sequencing in Alopecia Areata identifies rare mutations in KRT82

| PRJNA768921 | ENA

Whole exome sequencing in Alopecia Areata identifies rare mutations in KRT82

Project description:Whole exome sequencing in Alopecia Areata identifies rare mutations in KRT82

| PRJNA768920 | ENA

PPM1D mutations are oncogenic drivers of Diffuse Midline Gliomas and are sufficient to enhance glioma formation

Project description:The role of PPM1D mutations in de novo gliomagenesis has not been systematically explored. Here we analyze whole genomes sequences of 170 pediatric high-grade gliomas and find that truncating mutations in PPM1D that increase the stability of its phosphatase are clonal driver events in 11% of DMGs and are enriched in primary pontine tumors. Through the development of novel DMG mouse models, we show that PPM1D mutations potentiate gliomagenesis and that PPM1D activity is required for in vivo oncogenesis. Finally, we applied integrative phosphoproteomic and functional genomics assays and found that the oncogenic effects of PPM1D truncation converge on regulators of cell cycle, DNA damage response, and p53 pathways, revealing therapeutic vulnerabilities including MDM2 inhibition. Together, these findings highlight PPM1D mutations to represent a targetable driver of pediatric gliomas.

2021-07-11 | GSE179813 | GEO

Transcriptome splicing analysis in K562 cells expressing rare and private spliceosomal mutations

Project description:Transcriptome splicing analysis in K562 cells expressing rare and private spliceosomal mutations

| PRJNA559879 | ENA

Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to ER-directed therapies

Project description:Estrogen receptor positive (ER+) breast cancers that develop resistance to therapies that target the ER are the most common cause of breast cancer death. Beyond mutations in ER, which occur in 25-30% of patients treated with aromatase inhibitors (AIs), our understanding of clinical mechanisms of resistance to ER-directed therapies remains incomplete. We identified activating HER2 mutations in metastatic biopsies from eight patients with ER+ metastatic breast cancer who had developed resistance to ER-directed agents, including AIs, tamoxifen, and fulvestrant. Examination of treatment-naïve primary tumors in five patients revealed no evidence of pre-existing mutations in four of five patients, suggesting that these mutations were acquired under the selective pressure of ER-directed therapy. These mutations were mutually exclusive with ER mutations, suggesting a distinct mechanism of acquired resistance to ER-directed therapies. In vitro analysis confirmed that these mutations conferred estrogen independence. In addition, and in contrast to ER mutations, these mutations resulted in resistance to tamoxifen, fulvestrant, and the CDK4/6 inhibitor palbociclib. Resistance was overcome by combining ER-directed therapy with the irreversible HER2 kinase inhibitor neratinib, highlighting an effective treatment strategy in these patients.

2018-10-19 | GSE121411 | GEO

Detection of Oncogenic Tumor Mutations in the Urine and Blood of Lung and Colorectal Cancer Patients

Project description:The purpose of this study is to see whether gene mutations can be found in the urine or blood of lung cancer patients and urine of colorectal cancer patients. Gene mutations are when DNA in a gene is damaged in a way that changes the genetic message carried by that gene. Gene mutations can sometimes cause lung cancers. These gene mutations are only found in lung and colorectal cancer cells, not the normal cells in your body. All lung cancer tumors and colorectal cancer tumors are now tested for different gene mutations as their presence affects lung cancer treatment. Tumor samples obtained from a biopsy or surgery are typically tested for these gene mutations.

| 2170258 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data